

# Update of VTE Guideline

2016-11-05

계명대의대 내과

최원일

## Grades of recommendation: methodological quality

- High(A): consistent results from RCTs or observational studies with very strong association and secure generalization
- Moderate(B): inconsistent results from RCTs or RCTs with methodological limitations
- Low(C): unbiased observational studies(e.g. well-executed cohort studies)
- Very low(D): other observational studies (e.g. case series)

# Grades of recommendation: strength of recommendations

- Stronger recommendations(we recommend)
  - high-quality methods with large, precise effect
  - benefits much greater than downsides, or downsides much greater than benefits
  - do it or don't do it- we recommend
  - Grade 1
- Weak recommendations(we suggest)
  - lower-quality methods with imprecise estimate
  - benefits not clearly greater or smaller than downsides
  - values and preferences very important
  - probably do it or probably don't do it- we suggest
  - Grade 2

# Incidence of VTE

- Estimated to affect 350,000 to 600,000 Americans annually
- Contributing to at least 100,000 deaths per year
- Will increase with ageing population



## 질병 소분류(3단 상병) 통계

진료받은 모든 질병에 대한 통계를 2천여개의 한국표준질병·사인분류의 소분류로 조회하는 서비스입니다.

검색

**폐색전증 126**

질병코드 조회

입원외래별

성별/연령5세구간별

성별/연령10세구간별

요양기관종별

요양기관소재지별

기간구분

심사년도  진료년월

2011 ▼

~

2015 ▼

조회

연도별 환자수 추이 [단위:명]



환자수

※해당 년도의 값을 클릭하세요



**2011년**

**2012년**

**2013년**

**2014년**

**2015년**

# 질병 소분류(3단 상병) 통계

진료받은 모든 질병에 대한 통계를 2천여개의 한국표준질병·사인분류의 소분류로 조회하는 서비스입니다.

검색

기타 정맥의 색전증 및 혈전증 182

질병코드 조회

입원외래별

성별/연령5세구간별

성별/연령10세구간별

요양기관종별

요양기관소재지별

기간구분

심사년도  진료년월

2011

~

2015

조회

연도별 환자수 추이 [단위:명]



환자수

※해당 년도의 값을 클릭하세요



2011년


2012년

2013년


2014년


2015년

# Incidence of PE



# Age







**Figure 1.** Annual incidence of VTE among residents of Worcester MA 1986, by age and sex. (Reproduced by permission from Anderson FA, et al. *Arch Intern Med.* 1991;151:933–938.)

# Incidence by race

Idiopathic DVT per 1,000,000 older than 18




# Prevalence of VTE is predicted to double by 2050




VTE cases per 100,000:

| 2002 | 2003 | 2004 | 2005 | 2006 | 2008 | 2010 | 2015 | 2020 | 2025 | 2030 | 2035 | 2040 | 2045 | 2050 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| 317  | 341  | 371  | 401  | 422  | 426  | 432  | 453  | 478  | 505  | 527  | 544  | 556  | 563  | 567  |



# The CHRISTOPHER study

*JAMA 2006;295:172-9*



**3-month PE risk**  
0.5% (0.2 to 1.1)


**3-month PE risk**  
1.3% (0.7 to 2.2)

# Can CT be avoided?

- Systematic review: : Low probability in Well's score & D-dimer neg: 28% avoided
- Well's score & age adjusted D-dimer (age x 10mg/L) for pt > 50 y.o. : 33% avoided
- Well's score & and probability adjusted D-dimer currently studied

# Influence of Age on Diagnostic Characteristics and Clinical Usefulness of D-dimer

| Age (years) | Sensitivity(%) (95% CI) | Specificity*% (95% CI) | Patients with a DD <500mg/L(%) |
|-------------|-------------------------|------------------------|--------------------------------|
| <40         | 100(86 to 100)          | 67(86 to 74)           | 58                             |
| 40-49       | 100(86 to 100)          | 67(59 to 75)           | 56                             |
| 50-59       | 100(83 to 100)          | 56(47 to 65)           | 49                             |
| 60-69       | 100(94 to 100)          | 40( 3 to 49)           | 26                             |
| 70-79       | 99 (93 to 100)          | 26(19 to 34)           | 17                             |
| 80+         | 100(95 to 100)          | 9(4 to 18)             | 5                              |



# Age-adjusted Cut-off for D-dimer

**Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts**

Renée A Douma, physician,<sup>1</sup> Grégoire le Gal, physician,<sup>2</sup> Maaïke Söhne, physician,<sup>1</sup> Marc Righini, physician,<sup>3</sup> Pieter W Kamphuisen, physician,<sup>1</sup> Arnaud Perrier, professor,<sup>4</sup> Marieke J H A Kruij, physician,<sup>5</sup> Henri Bounameaux, professor,<sup>3</sup> Harry R Büller, professor,<sup>1</sup> Pierre-Marie Roy, professor<sup>6</sup>

# Age-adjusted DD cut-off in suspected PE

Derivation set

N=1721

Prevalence of PE:24%

**Age-adjusted  
Cut-off value:  
Age  $\geq$  20 ( $\mu\text{g/L}$  FEU)  
Above 50 years**

(1 FEU=2 x DDU)





Fig1) Optimal cut-off values for D-dimer test for pulmonary embolism by age in patients with an unlikely clinical probability of pulmonary embolism (sensitivity set at 100%)

# Age-adjusted Diagnostic Thresholds for D-dimer



- This allows increasing specificity (~40%) while retaining a sensitivity >97%
- Such a strategy deserves to be prospectively evaluated in management studies of patients suspected of VTE


Original Investigation

# Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism The ADJUST-PE Study

Marc Righini, MD; Josien Van Es, MD, PhD; Paul L. Den Exter, MD; Pierre-Marie Roy, MD, PhD; Franck Verschuren, MD; Alexandre Ghuysen, MD; Olivier T. Rutschmann, MD; Olivier Sanchez, MD; Morgan Jaffrelot, MD; Albert Trinh-Duc, MD; Catherine Le Gall, MD; Farès Moustafa, MD; Alessandra Principe, MD; Anja A. Van Houten, MD; Marije Ten Wolde, MD, PhD; Renée A. Douma, MD, PhD; Germa Hazelaar, MD; Petra M. G. Erkens, PhD; Klaas W. Van Kralingen, MD; Marco J. J. H. Grootenboers, MD, PhD; Marc F. Durian, MD; Y. Whitney Cheung, MD; Guy Meyer, MD; Henri Bounameaux, MD; Menno V. Huisman, MD, PhD; Pieter W. Kamphuisen, MD, PhD; Grégoire Le Gal, MD, PhD

- A multicenter, prospective management study evaluating the age adjusted cut-off in a cohort of 3346 patients with suspected PE.
- Patients with a normal age-adjusted D-dimer value did not undergo CT pulmonary angiography and were left untreated and followed up three month period.

# ADJUST PE: Study Design and Results



# ADJUST PE: Patient $\geq 75$ years

- 766 patients  $\geq 75$  years
- 673 with low or intermediate clinical probability
- D-dimer  $< 500 \mu\text{g/L}$ : 43 (6.4%)
- D-dimer  $< \text{age} \times 10$ : 200 (29.7%)
- 3-month VTE: 0/195

Original Investigation


# Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism The ADJUST-PE Study

Marc Righini, MD; Josien Van Es, MD, PhD; Paul L. Den Exter, MD; Pierre-Marie Roy, MD, PhD; Franck Verschuren, MD; Alexandre Ghuysen, MD; Olivier T. Rutschmann, MD; Olivier Sanchez, MD; Morgan Jaffrelot, MD; Albert Trinh-Duc, MD; Catherine Le Gall, MD; Farès Moustafa, MD; Alessandra Principe, MD; Anja A. Van Houten, MD; Marije Ten Wolde, MD, PhD; Renée A. Douma, MD, PhD; Germa Hazelaar, MD; Petra M. G. Erkens, PhD; Klaas W. Van Kralingen, MD; Marco J. J. H. Grootenboers, MD, PhD; Marc F. Durian, MD; Y. Whitney Cheung, MD; Guy Meyer, MD; Henri Bounameaux, MD; Menno V. Huisman, MD, PhD; Pieter W. Kamphuisen, MD, PhD; Grégoire Le Gal, MD, PhD

## CONCLUSIONS:

- Compared with a fixed D-dimer cutoff of 500  $\mu\text{g/L}$ , the combination of pretest clinical probability assessment with age-adjusted D-dimer cutoff was associated with a larger number of patients in whom PE could be considered ruled out with a low likelihood of subsequent clinical VTE.

# Diagnostic Evaluation of Patients with Suspected Pulmonary Embolism



# Can my PE-patient in ER go home?

- Pulmonary Embolism Severity Index(PESI)

|                  |       |           |     |
|------------------|-------|-----------|-----|
| -Age             | 1p/yr | SBP<100   | 30p |
| -Male sex        | 10p   | Pulse>110 | 20p |
| -Cancer          | 30p   | RR>30     | 20p |
| -CHF             | 10p   | Temp<36   | 20p |
| -Chron lung dis. | 10p   | SaO2<90%  | 20p |
| -△ mental status | 60p   |           |     |

85 p or less= low risk of fatal PE-NPV=99%

Aujeusky D et al. Am J Resp Crit Care Med 2005;172:1041-6

External validation in : J Intern Med 2007;261:597-604

# Simplified PESI


- Retrospective analysis of RIETE registry

|                              |    |
|------------------------------|----|
| Age>80                       | 1P |
| History of Cancer            | 1P |
| Chronic cardiopulmonary dis. | 1P |
| Pulse>110                    | 1P |
| SBP<100                      | 1P |
| SaO <sub>2</sub> <90%        | 1P |

0=low risk, 1 or more= high risk

Jiménez D et al. Arch Intern Med. 2010;170:1383-9

# Simplified PESI result



# High-risk PE

- Hemodynamically unstable-systolic BP<90mmHg-mortality is 58%. Grade 2B
- Thrombolysis-preferred route is I.V. Grade 2C
- Reduces mortality by =42% and recurrence by 50%
- But increases major hemorrhage 2.8-fold and intracranial hemorrhage 3.6-6.8-fold

# Hemodynamically stable with RV-strain

| Outcome             | Tenecteplase<br>(N=506) | Placebo<br>(N=498) | Odds ratio<br>(95% CI) | P-value |
|---------------------|-------------------------|--------------------|------------------------|---------|
| All cause           | 6(1.2%)                 | 9(1.8%)            | 0.65(0.23-1.85)        | 0.42    |
| Mortality           |                         |                    |                        |         |
| Hemodynamic         | 8(1.6%)                 | 25(5.0%)           | 0.30(0.14-0.68)        | 0.002   |
| Decompensation      |                         |                    |                        |         |
| Major               | 32(6.3%)                | 6(1.2%)            | 5.55(2.3-13.4)         | <0.001  |
| Extracranial        |                         |                    |                        |         |
| Bleeding            |                         |                    |                        |         |
| Stroke <sup>a</sup> | 12(2.4%)                | 1(0.2%)            | 12.1(1.6-93.4)         | 0.001   |

# Thrombolysis for large DVT

Meta-analysis of trial with catheter directed thrombolysis

| <b>Outcome</b>                   | <b>Odds ratio</b> | <b>95% CI</b> |
|----------------------------------|-------------------|---------------|
| Complete lysis within 30days     | 91                | 19.3-429      |
| Patency at 6months               | 5.77              | 1.99-16.7     |
| Reduced post-thrombotic syndrome | 0.4               | 0.19-0.96     |
| Venous obstruction               | 0.20              | 0.09-0.44     |
| Major bleeding                   | 2.0               | 1.62-2.62     |

# NOACs for treatment of VTE

- Cochrane meta-analysis of 11 randomized trials-major bleeds are fewer in DVT:
  - Thrombin inhibitors: odds ratio 0.68; 95% CI, 0.47-0.98
  - Xa inhibitors: odds ratio 0.57;95% CI,0.43-0.76
- No difference in PE for recurrence, mortality or major bleeds
- ACCP 2016 suggests NOACs rather than VKA

Grade 2B

# Treatment for special patient group

- VTE and Cancer: LMWH first 3 months
- Elderly patients(>75): meta-analysis shows NOACs more effective than VKA, odds ratio 0.45;95%CI,0.27-0.77  
NO increase in bleeding, odds ratio 1.02;95% CI, 0.73-1.43  
or lower : relative risk 0.49;95% CI,0.25-0.96
- Renal failure(CrCl 30-49)-NOACs vs. VKA
  - Efficacy: relative risk 0.70;95% CI, 0.43-1.15
  - Major bleeds: relative risk 0.51; 95% CI, 0.26-0.99

Grade 2C

# Duration of anticoagulation

## ACCP 2016

- Extended duration for
  - Second event or Cancer Grade 1B
  - 1<sup>st</sup> unprovoked VTE & low-moderate risk of bleeding Grade 2B
- Most other patients-3 months

# Additional risk factors for recurrence

- Male sex
- Elevated D-dimer 1 month after stopping
- Residual thrombosis

# Clinical prediction rules

| Name, ref                    | Components  | Interpretation  |
|------------------------------|---|---|
| Vienna                       | Male sex<br>Proximal DVT and/ or PE<br>Elevated D-dimer   | Nomogram with continuous<br>Model                                     |
| DASH                         | D-dimer<br>Age<br>Sex<br>Hormonal therapy   | Score $\leq 1$ → annual risk 3.1%                                     |
| Men continue<br>And HER DOO2 | Post- thrombotic signs<br>D-dimer $\geq 250$ mg/L<br>Body mass index $\geq 30$<br>Age $\geq 65$ | (only for females)<br>0 or 1 of the criteria → annual<br>Risk $< 3\%$ |

# Perhaps no anticoagulation?

- Distal DVT without risk factors

Grade 2C

-In that case, consider serial ultrasound for 2w

- Subsegmental PE without risk factors

-Do bilateral CUS of the legs.

-In case of risk factors- anticoagulate

Grade 2C

# Risk factors supporting Rx

## Distal deep vein thrombosis

External thrombus(>5cm) or present in several veins

Location close to proximal veins

Permanent provoking risk factor or unprovoked thrombosis

Active cancer

Hospitalized patient

Previous venous thromboembolism

High D-dimer level without another apparent cause

## Subsegmental pulmonary embolism

Marked symptoms, not attributable to other cause

Low cardiopulmonary reserve

Permanent provoking risk factor or unprovoked thrombosis

Active cancer

Hospitalized patient

Previous venous thromboembolism

# Compression stockings?

- Compression stockings for 2 years did not reduce post-thrombotic syndrome or pain
- Stockings are not recommended for routinely use in DVT
- Patients with symptoms may benefit

Grade 2B

# IVC Filter?

- VTE treated with anticoagulants, we recommend against an IVC filter (Grade 1B).
- The PREPIC 2 randomized trial found that placement of an IVC filter for 3 months did not reduce recurrent PE, including fatal PE, in anticoagulated patients with PE and DVT who had additional risk factors for recurrent VTE

# For recurrent VTE

- For recurrent VTE on a non-LMWH anticoagulant, we suggest LMWH (Grade 2C),
- For recurrent VTE on LMWH we suggest increasing the LMWH dose (Grade 2C).

# Conclusions

- VTE is an increasing problem
- Several risk scores and risk stratification tools are available and should be used
- Diagnostic algorithm for DVT/PE is helpful
- Many options for treatment of VTE exist
- Decide at 3-6months regarding stopping or indefinite anticoagulation